D.A. Davidson & Co’s Titan Pharmaceuticals TTNP Stock Holding History

D.A. Davidson & Co’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1	Closed	-$9K	–	1925
2017 Q2	$9K	Sell	1 -2	-67%	-$18.6K	﹤0.01%	2076
2017 Q1	$33K	Hold	3	–	–	﹤0.01%	1670
2016 Q4	$40K	Hold	3	–	–	﹤0.01%	1695
2016 Q3	$58K	Hold	3	–	–	﹤0.01%	1460
2016 Q2	$54K	Sell	3 -8	-73%	-$170K	﹤0.01%	1394
2016 Q1	$191K	Buy	+11	New	+$147K	0.01%	864

Other funds holding TTNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MERSOM

Municipal Employees' Retirement System of Michigan Lansing, Michigan $8.81B AUM 10.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WPA

Winning Points Advisors Boca Raton, Florida $74.8M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

D.A. Davidson & Co's TTNP Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Titan Pharmaceuticals (TTNP) in Q3 2017, closing a stake of 1 share — an estimated $9K sold.

D.A. Davidson & Co first reported a position in TTNP in Q1 2016 and held it in 6 quarters. The position peaked at $191K in Q1 2016. 24 funds tracked by Wall St. Rank hold TTNP as of Q3 2017.

D.A. Davidson & Co reported no remaining Titan Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
D.A. Davidson & Co sold 1 Titan Pharmaceuticals share in Q3 2017, an estimated $9K.
D.A. Davidson & Co first reported a position in Titan Pharmaceuticals in Q1 2016 and held it in 6 quarters.
D.A. Davidson & Co's Titan Pharmaceuticals position peaked at $191K in Q1 2016.
24 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.